SciELO - Scientific Electronic Library Online

 
vol.89 número2Factores sociodemográficos y clínicos asociados a la recepción de cuidado informal en pacientes con neoplasia hematológica: estudio basado en las diferentes etapas del tratamientoIncidencia de la infección por Bartonella henselae en la Comunidad Valenciana durante el período 2009-2012 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Salud Pública

versión On-line ISSN 2173-9110versión impresa ISSN 1135-5727

Resumen

OSCA GUADALAJARA, Marta; GUADALAJARA OLMEDA, Natividad  y  ESCARTIN MARTINEZ, Rosario. Impact of Teriparatide on Quality of Life in Osteoporotic Patients. Rev. Esp. Salud Publica [online]. 2015, vol.89, n.2, pp.215-225. ISSN 2173-9110.  http://dx.doi.org/10.4321/S1135-57272015000200009.

Background: Lost bone in osteoporotic patients increases the risk of fractures and back pain, and decreases quality of life. The aim of this study was to analyse the effect of teriparatide (TPTD) in osteoporotic patients with vertebral pain. Methods: A prospective observational study between April 2006 and February 2014 was done with 77 patients treated with teriparatide in the Pain Unit of Hospital Obispo Polanco of Teruel (Spain). Treatment duration was 18 or 24 months. Pain was assessed by the Visual Analogue Scale (VAS). Health-related quality of life was measured using the European Quality of Life Questionnaire (EuroQol-5D) in order to obtain the social tariff (ST). Pre and post-treatment values were collected respectively. A descriptive and regression analysis was done. Results: Improvement in pain was observed (80%) and in health-related quality of life (65%). The mean VAS improved (from 5.42 to 3.47 points) and the mean health status value too (from 0.36 to 0.58 points). The regression indicated an improvement of VAS in 0.441 for each initial VAS point, and of ST in 0.0528 points for each 0.1 initial ST point. The probability of VAS reduction in 3 points (OR = 2.021) was greater than in 2 points (OR = 1.695). Conclusions: TPTD reduces pain and improves quality of life of osteoporotic patients. The worse the baseline situation, the more patients' health improved, so it could be used as criteria for therapeutic decisions and health management.

Palabras clave : Back pain; Osteoporosis; Quality of life; Teriparatide.

        · resumen en Español     · texto en Español     · Español ( pdf )